Indications for Use Sample Clauses

Indications for Use. The eSVS Mesh is indicated for improving saphenous vein bypass graft patency in patients undergoing coronary artery bypass graft procedures utilizing autologous saphenous vein grafts with external diameters from 3.6 mm to 7.0 mm and double wall thicknesses less than 1.4 mm. Ordering Information: Fits Saphenous Vein eSVS Mesh Grafts Between: Catalog Order Diameter Minimum Maximum Number Pricing 3.5 mm 3.6 mm 4.1 mm eSVS 3.5 USD $2,000 4.0 mm 4.2 mm 5.4 mm eSVS 4.0 USD $2,000 4.5 mm 5.5 mm 7.0 mm eSVS 4.5 USD $2,000 Company Contact Information: Kips Bay Medical, Inc. Phone: +0.000.000.0000 0000 Xxxxxxxxx Xxxx, Xxxxx 000 Fax: +0.000.000.0000 Xxxxxxxxxxx, XX 00000 XXX xxx.xxxxxxxxxxxxxx.xxx
Sample 1Sample 2Sample 3See All (13)
AutoNDA by SimpleDocs
Indications for Use. The DataCaptorTM System is indicated for use in data collection and clinical information management either directly or through networks with independent bedside devices. DataCaptorTM is not intended for monitoring purposes, nor is the software intended to control any of the clinical devices (independent bedside devices / information systems) it is connected to.
Sample 1Sample 2
Indications for Use. [***] is a leading cause of [***], and transmission to the [***] can be prevented through the use of prophylactic antibiotics during [***]. Currently [***] are screened at [***] by culture to determine their [***] status, following established [***] guidelines. Studies have demonstrated significant improvement in detection and turnaround time using molecular techniques. These specimens would be batched for testing. Ultimately, point of care testing will expand this testing to individuals without [***] care at the time of [***].
Sample 1Sample 2
Indications for Use. 1. A known or suspected case of highly infectious disease that may have been acquired via travel, health care provider, or lab.
Sample 1Sample 2
Indications for Use. The VOLCANO s5i-GE Imaging System is used for the qualitative and quantitative evaluation of vascular morphology in the coronary arteries and vessels of the peripheral vasculature. It is also indicated as an adjunct to conventional angiographic procedures to provide an image of vessel lumen and wall structures. ChromaFlo is indicated for qualitative blood flow information from peripheral and coronary vasculature; flow information can be an adjunct to other methods of estimating blood flow and blood perfusion.
Sample 1
Indications for Use. The eSVS Mesh is indicated for improving saphenous vein bypass graft patency in patients undergoing coronary artery bypass graft procedures utilizing autologous saphenous vein grafts with external diameters from 3.6 mm to 7.0 mm and double wall thicknesses less than 1.4 mm. Ordering Information: Fits Saphenous Vein eSVS Mesh Grafts Between: Catalog Order Diameter Minimum Maximum Number Pricing 3.5 mm 3.6 mm 4.1 mm eSVS 3.5 USD $2,000 4.0 mm 4.2 mm 5.4 mm eSVS 4.0 USD $2,000 4.5 mm 5.5 mm 7.0 mm eSVS 4.5 USD $2,000 For order quantities of 11 or more the price shall be $1,200 USD for each unit. Company Contact Information: Kips Bay Medical, Inc. Phone: +0.000.000.0000 0000 Xxxxxxxxx Xxxx, Xxxxx 000 Fax: +0.000.000.0000 Xxxxxxxxxxx, XX 00000 XXX xxx.xxxxxxxxxxxxxx.xxx
Sample 1
Indications for Use. The indications for use on the labels, notices or other commercial documents issued by Seller are based on official and private test results which have been most consistent in practice. They are not absolute rules, but general recommendations which must be adapted to the particular case of any treatment, because of the many factors beyond Seller's control, such as the nature of the soil, plant varieties and the particular sensitivity of the crop, special atmospheric conditions, equipment and application conditions, etc. Seller assumes no liability for such general indications as they must be adapted to each particular case, even in the absence of contraindications.
Sample 1
AutoNDA by SimpleDocs

Related to Indications for Use

  • Supply of Materials The following materials will be supplied by the department Name of Materials Rate. Place of delivery 1.

  • Research Records Each Party shall maintain records of each Research Program (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of such Research Program. All laboratory notebooks shall be maintained for no less than the term of any Patent issuing therefrom. All other records shall be maintained by each Party during the relevant Research Term and for [**] thereafter. All such records of a Party shall be considered such Party’s Confidential Information.

  • License; Use Upon delivery to an Authorized Person or a person reasonably believed by Custodian to be an Authorized Person of the Fund of software enabling the Fund to obtain access to the System (the “Software”), Custodian grants to the Fund a personal, nontransferable and nonexclusive license to use the Software solely for the purpose of transmitting Written Instructions, receiving reports, making inquiries or otherwise communicating with Custodian in connection with the Account(s). The Fund shall use the Software solely for its own internal and proper business purposes and not in the operation of a service bureau. Except as set forth herein, no license or right of any kind is granted to the Fund with respect to the Software. The Fund acknowledges that Custodian and its suppliers retain and have title and exclusive proprietary rights to the Software, including any trade secrets or other ideas, concepts, know-how, methodologies, or information incorporated therein and the exclusive rights to any copyrights, trademarks and patents (including registrations and applications for registration of either), or other statutory or legal protections available in respect thereof. The Fund further acknowledges that all or a part of the Software may be copyrighted or trademarked (or a registration or claim made therefor) by Custodian or its suppliers. The Fund shall not take any action with respect tot the Software inconsistent with the foregoing acknowledgement, nor shall the Fund attempt to decompile, reverse engineer or modify the Software. The Fund may not xxx, sell, lease or provide, directly or indirectly, any of the Software of any portion thereof to any other person or entity without Custodian’s prior written consent. The Fund may not remove any statutory copyright notice or other notice included in the Software or on any media containing the Software. The Fund shall reproduce any such notice on any reproduction of the Software and shall add any statutory copyright notice or other notice to the Software or media upon Custodian’s request.

  • Research Reports Distributor acknowledges that Dealer may prepare research reports relating to the Fund that are not to be used for marketing purposes (“Research Reports”). Distributor hereby authorizes Dealer to use the name of the Fund, Distributor and BREDS in Research Reports.

  • Review of Materials During the term of this Agreement, Client shall ensure that all prospectuses, statements of additional information, registration statements, proxy statements, reports to shareholders, advertising and sales literature or other materials prepared for distribution to Fund shareholders or the public, which refer to the Subadviser in any way, prepared by employees or agents of Client or its affiliates are consistent with information previously provided by Subadviser. Subadviser shall promptly notify the Client of any changes to information pertaining to the Subadviser and stated in the materials described in this Section 6(g).

  • No Improper Use of Materials During his or her employment with the Company, Employee will not improperly use or disclose any Confidential Information or trade secrets, if any, of any former employer or any other person to whom Employee has an obligation of confidentiality, and Employee will not bring onto the premises of the Company any unpublished documents or any property belonging to any former employer or any other person to whom Employee has an obligation of confidentiality unless consented to in writing by that former employer or person.

  • Development Records Each Party shall maintain complete, current and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner [*]. Each Party shall document all non-clinical studies and clinical trials in formal written study reports according to applicable Laws and national and international guidelines (e.g., ICH, GCP, GLP, and GMP). Each Party shall have the right to review and copy such records maintained by the other Party at reasonable times and to obtain access to the original [*].

  • Advertising and Promotional Materials The Purchaser acknowledges and agrees that the Vendor shall have the right to use drawings, photographs, videos or other depictions of the interior and/or exterior of the Dwelling and/or the Subdivision or any components or features thereof in any promotional or advertising materials without notice to or consent from the Purchaser being required in any manner whatsoever.

  • Product Information EPIZYME recognizes that by reason of, inter alia, EISAI’s status as an exclusive licensee in the EISAI Territory under this Agreement, EISAI has an interest in EPIZYME’s retention in confidence of certain information of EPIZYME. Accordingly, until the end of all Royalty Term(s) in the EISAI Territory, EPIZYME shall keep confidential, and not publish or otherwise disclose, and not use for any purpose other than to fulfill EPIZYME’s obligations, or exercise EPIZYME’s rights, hereunder any EPIZYME Know-How Controlled by EPIZYME or EPIZYME Collaboration Know-How, in each case that are primarily applicable to EZH2 or EZH2 Compounds (the “Product Information”), except to the extent (a) the Product Information is in the public domain through no fault of EPIZYME, (b) such disclosure or use is expressly permitted under Section 9.3, or (c) such disclosure or use is otherwise expressly permitted by the terms and conditions of this Agreement. For purposes of Section 9.3, each Party shall be deemed to be both the Disclosing Party and the Receiving Party with respect to Product Information. For clarification, the disclosure by EPIZYME to EISAI of Product Information shall not cause such Product Information to cease to be subject to the provisions of this Section 9.2 with respect to the use and disclosure of such Confidential Information by EPIZYME. In the event this Agreement is terminated pursuant to Article 12, this Section 9.2 shall have no continuing force or effect, but the Product Information, to the extent disclosed by EPIZYME to EISAI hereunder, shall continue to be Confidential Information of EPIZYME, subject to the terms of Sections 9.1 and 9.3 for purposes of the surviving provisions of this Agreement. Each Party shall be responsible for compliance by its Affiliates, and its and its Affiliates’ respective officers, directors, employees and agents, with the provisions of Section 9.1 and this Section 9.2.

Time is Money Join Law Insider Premium to draft better contracts faster.